CSIMarket
 


Cryoport inc   (CYRX)
Other Ticker:  
 

Cryoport Inc 's Leverage Ratio

CYRX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of -4.78% Cryoport Inc improved Leverage Ratio in third quarter 2023 to 0.86, above the Cryoport Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 215 other companies have achieved lower Leverage Ratio than Cryoport Inc in the III Quarter 2023. While Leverage Ratio total ranking has improved so far in the third quarter 2023 to 1148, from total ranking in the second quarter 2023 at 1629 .

Explain Leverage Ratio?
Who are CYRX Customers?
What are CYRX´s Total Liabilities?


CYRX Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -3.27 % -4.25 % -8.03 % -13.4 % -14.14 %
Y / Y Total Liabilities Change -2.38 % 2.52 % 4.21 % 2.49 % 172.7 %
Leverage Ratio MRQ 0.86 0.89 0.87 0.86 0.85
CYRX's Total Ranking # 1148 # 1629 # 1664 # 790 # 1665
Seq. Equity Change -1.24 % -2.9 % 0.84 % 0.02 % -2.23 %
Seq. Total Liabilities Change -4.78 % -0.25 % 1.87 % 0.89 % -0 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 216
Healthcare Sector # 428
Overall Market # 1148


Leverage Ratio Statistics
High Average Low
5.8 0.71 0.07
(Dec 31 2011)   (Dec 31 2019)




Financial Statements
Cryoport Inc 's Equity $ 538 Millions Visit CYRX's Balance sheet
Cryoport Inc 's Total Liabilities $ 463 Millions Visit CYRX's Balance sheet
Source of CYRX's Sales Visit CYRX's Sales by Geography


Cumulative Cryoport Inc 's Leverage Ratio

CYRX's Leverage Ratio for the trailling 12 Months

CYRX Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -3.27 % -4.25 % -8.03 % -13.4 % -14.14 %
Y / Y Total Liabilities TTM Growth -2.38 % 2.52 % 4.21 % 2.49 % 172.7 %
Leverage Ratio TTM 0.87 0.87 0.85 0.83 0.79
Total Ranking TTM # 8 # 1553 # 6 # 699 # 8
Seq. Equity TTM Growth -1.24 % -2.9 % 0.84 % 0.02 % -2.23 %
Seq. Total Liabilities TTM Growth -4.78 % -0.25 % 1.87 % 0.89 % -0 %


On the trailing twelve months basis Due to repayements of liabilities of -4.78% Cryoport Inc has not changed Leverage Ratio in the 12 months ending in III Quarter 2023 to 0.87, above the Cryoport Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry CYRX recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 8, from total ranking in previous 12 month period at 1553.

Explain Leverage Ratio?
Who are CYRX Customers?
What are CYRX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 8


trailing twelve months Leverage Ratio Statistics
High Average Low
1.41 0.47 0.12
(Sep. 30, 2015)   (Sep 30 2018)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Proqr Therapeutics N v   2.33 $ 108.072  Millions$ 46.357  Millions
Gossamer Bio Inc   2.33 $ 243.308  Millions$ 104.617  Millions
Phibro Animal Health Corporation  2.27 $ 620.465  Millions$ 273.069  Millions
Uniqure N v   2.21 $ 594.878  Millions$ 268.784  Millions
Biovie Inc   2.15 $ 16.212  Millions$ 7.548  Millions
Bristol myers Squibb Company  2.14 $ 62,265.000  Millions$ 29,062.000  Millions
G1 Therapeutics Inc   2.09 $ 90.075  Millions$ 43.022  Millions
Milestone Pharmaceuticals inc   2.06 $ 58.612  Millions$ 28.504  Millions
Cerevel Therapeutics Holdings Inc   2.01 $ 549.000  Millions$ 272.962  Millions
Abeona Therapeutics Inc   2.00 $ 44.049  Millions$ 22.038  Millions
Travere Therapeutics Inc   1.98 $ 553.084  Millions$ 279.766  Millions
Maravai Lifesciences Holdings Inc   1.96 $ 1,748.259  Millions$ 892.281  Millions
Jazz Pharmaceuticals Plc  1.92 $ 6,684.082  Millions$ 3,489.373  Millions
Cyclacel Pharmaceuticals Inc   1.91 $ 8.200  Millions$ 4.297  Millions
Syros Pharmaceuticals Inc   1.87 $ 67.800  Millions$ 36.302  Millions
Ibio inc   1.85 $ 24.469  Millions$ 13.209  Millions
Veru Inc   1.85 $ 32.813  Millions$ 17.783  Millions
Catalyst Biosciences Inc   1.83 $ 6.447  Millions$ 3.517  Millions
Clene Inc   1.82 $ 39.027  Millions$ 21.406  Millions
Zoetis Inc   1.78 $ 9,028.000  Millions$ 5,074.000  Millions
Nektar Therapeutics  1.77 $ 282.876  Millions$ 159.368  Millions
Cv Sciences Inc   1.74 $ 6.061  Millions$ 3.479  Millions
Blue Water Biotech Inc   1.72 $ 17.645  Millions$ 10.236  Millions
Emergent Biosolutions Inc   1.72 $ 1,195.900  Millions$ 697.200  Millions
Flora Growth Corp   1.70 $ 22.365  Millions$ 13.122  Millions
Alimera Sciences Inc   1.68 $ 81.943  Millions$ 48.840  Millions
Soligenix inc   1.65 $ 6.963  Millions$ 4.221  Millions
Promis Neurosciences inc   1.65 $ 11.121  Millions$ 6.755  Millions
Catalent Inc   1.61 $ 6,182.000  Millions$ 3,841.000  Millions
Amphastar Pharmaceuticals Inc   1.60 $ 949.493  Millions$ 595.140  Millions

Date modified: 2023-11-12T06:27:51+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com